Bi-HPDO3A as a novel contrast agent for X-ray computed tomography

Area of Science:

• Materials Science
• Radiology
• Nanotechnology

Background:

• Computed tomography (CT) imaging is crucial in medical diagnostics.
• Development of novel contrast agents is essential for improving CT efficacy.
• Bismuth-based materials offer potential as CT contrast agents due to their high atomic number.

Purpose of the Study:

• To synthesize a novel bismuth-based contrast agent for CT imaging.
• To evaluate the in vitro and in vivo characteristics of the synthesized agent.
• To compare the efficacy of the new agent with a clinically approved agent.

Main Methods:

• Facile synthesis strategy employed for bismuth-based agent preparation.
• In vitro evaluation of stability, toxicity, and CT performance.
• In vivo CT imaging conducted at multiple doses (0.5, 1.2, and 5 mmol/kg).
• Comparative analysis with iopamidol at 1.2 mmol/kg.

Main Results:

• Successful synthesis of a new bismuth-based CT agent.
• Favorable in vitro stability and low toxicity observed.
• Effective in vivo CT imaging performance demonstrated.
• Comparable results to iopamidol at equivalent dosages.

Conclusions:

• The facile synthesis strategy yielded a promising bismuth-based CT contrast agent.
• The agent exhibits suitable in vitro and in vivo properties for CT applications.
• This new agent holds potential as an alternative to existing CT contrast agents.